Skip to main content
Erschienen in: Obesity Surgery 12/2014

01.12.2014 | Original Contributions

Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum

verfasst von: Francieli Rohden, Cintia S. Costa, Thais O. Hammes, Rogério Margis, Alexandre V. Padoin, Cláudio C. Mottin, Regina Maria Guaragna

Erschienen in: Obesity Surgery | Ausgabe 12/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Bariatric surgery is the most effective therapeutic option for obesity and its complications, especially in type 2 diabetes. The aim of this study was to investigate the messenger RNA (mRNA) gene expression of proglucagon, glucose-dependent insulinotropic peptide (GIP), prohormone convertase 1/3 (PC1/3), and dipeptidyl peptidase-IV (DPP-IV) in jejunum cells of the morbidly obese (OB) non type 2 diabetes mellitus (NDM2) and type 2 diabetes mellitus (T2DM), to determine the molecular basis of incretin secretion after bariatric surgery.

Methods

Samples of jejunal mucosa were obtained from 20 NDM2 patients: removal of a section of the jejunum about 60 cm distal to the ligament of Treitz and 18 T2DM patients: removal of a section of the jejunum about 100 cm distal to the ligament of Treitz. Total RNA was extracted using TRIzol. Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) was carried out. Samples were sequenced to PC1/3 by ACTGene Análises Moleculares Ltd. Immuno content was quantified with a fluorescence microscope.

Results

T2DM showed decreased PC1/3 mRNA expression in the primers tested (primer a, p = 0.014; primer b, p = 0.048). Many patients (36.5 %) did not express PC1/3 mRNA. NDM2 and T2DM subjects showed nonsignificantly different proglucagon, GIP, and DPP-IV mRNA expression. The immuno contents of glucagon-like peptide-1 and GIP decreased in T2DM jejunum, but incubation with high glucose stimulated the immuno contents.

Conclusions

The results suggest that bioactivation of pro-GIP and proglucagon could be impaired by the lower expression of PC1/3 mRNA in jejunum cells of obese patients with T2DM. However, after surgery, food could activate this system and improve glucose levels in these patients.
Literatur
1.
Zurück zum Zitat Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–37.PubMedCentralPubMed Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–37.PubMedCentralPubMed
2.
Zurück zum Zitat Abbatini F, Rizzello M, Casella G, et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010;24:1005–10.PubMedCrossRef Abbatini F, Rizzello M, Casella G, et al. Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and adjustable gastric banding on type 2 diabetes. Surg Endosc. 2010;24:1005–10.PubMedCrossRef
3.
Zurück zum Zitat Salinari S, Bertuzzi A, Guidone C, et al. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg. 2013;257:462–8.PubMedCrossRef Salinari S, Bertuzzi A, Guidone C, et al. Insulin sensitivity and secretion changes after gastric bypass in normotolerant and diabetic obese subjects. Ann Surg. 2013;257:462–8.PubMedCrossRef
4.
Zurück zum Zitat Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012;303:E122–31.PubMedCrossRef Jorgensen NB, Jacobsen SH, Dirksen C, et al. Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol Metab. 2012;303:E122–31.PubMedCrossRef
5.
Zurück zum Zitat Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110:571–84.PubMedCrossRef Beckman LM, Beckman TR, Earthman CP. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass procedure: a review. J Am Diet Assoc. 2010;110:571–84.PubMedCrossRef
6.
Zurück zum Zitat Beckman LM, Beckman TR, Sibley SD, et al. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. J Parenter Enteral Nutr. 2011;35:169–80.CrossRef Beckman LM, Beckman TR, Sibley SD, et al. Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery. J Parenter Enteral Nutr. 2011;35:169–80.CrossRef
7.
Zurück zum Zitat Varela EJ. Bariatric surgery: a cure for diabetes? Curr Opin Clin Nutr Metab Care. 2011;14:396–401.PubMedCrossRef Varela EJ. Bariatric surgery: a cure for diabetes? Curr Opin Clin Nutr Metab Care. 2011;14:396–401.PubMedCrossRef
8.
Zurück zum Zitat Hamza N, Abbas MH, Darwish A, et al. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis. 2011;7:691–6.PubMedCrossRef Hamza N, Abbas MH, Darwish A, et al. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis. 2011;7:691–6.PubMedCrossRef
9.
10.
Zurück zum Zitat Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22:1084–96.PubMedCrossRef Jacobsen SH, Olesen SC, Dirksen C, et al. Changes in gastrointestinal hormone responses, insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-diabetic subjects. Obes Surg. 2012;22:1084–96.PubMedCrossRef
11.
Zurück zum Zitat Rondas D, D’Hertog W, Overbergh L, et al. Glucagon-like peptide-1: modulator of β-cell dysfunction and death. Diabetes, Obes Metab. 2013;15(3):185–92.CrossRef Rondas D, D’Hertog W, Overbergh L, et al. Glucagon-like peptide-1: modulator of β-cell dysfunction and death. Diabetes, Obes Metab. 2013;15(3):185–92.CrossRef
12.
Zurück zum Zitat Ranganath LR. The entero-insular axis: implications for human metabolism. Clin Chem Lab Med. 2008;46(1):43–56.PubMedCrossRef Ranganath LR. The entero-insular axis: implications for human metabolism. Clin Chem Lab Med. 2008;46(1):43–56.PubMedCrossRef
13.
Zurück zum Zitat Hellstro PM, Slund ENA, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008;20:649–59.CrossRef Hellstro PM, Slund ENA, Edholm T, et al. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil. 2008;20:649–59.CrossRef
14.
Zurück zum Zitat Gautier JF, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31:233–42.PubMedCrossRef Gautier JF, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31:233–42.PubMedCrossRef
15.
Zurück zum Zitat Martín MG, Lindberg I, Solorzano-Vargas RS, et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology. 2013;145:138–48.PubMedCentralPubMedCrossRef Martín MG, Lindberg I, Solorzano-Vargas RS, et al. Congenital proprotein convertase 1/3 deficiency causes malabsorptive diarrhea and other endocrinopathies in a pediatric cohort. Gastroenterology. 2013;145:138–48.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Ducker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316–23.CrossRef Ducker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316–23.CrossRef
17.
Zurück zum Zitat Burcelin R, Thorens B. Incretins: what is known, new and controversial in 2013? Diabetes Metab. 2013;39(2):89–93.PubMedCrossRef Burcelin R, Thorens B. Incretins: what is known, new and controversial in 2013? Diabetes Metab. 2013;39(2):89–93.PubMedCrossRef
18.
Zurück zum Zitat Damholt AB, Bucham AM, Kofod H. Glucagon-like-peptide-1 secretion from canine L-cells is increase by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology. 1998;139:2085–91.PubMedCrossRef Damholt AB, Bucham AM, Kofod H. Glucagon-like-peptide-1 secretion from canine L-cells is increase by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology. 1998;139:2085–91.PubMedCrossRef
19.
Zurück zum Zitat Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes a new perspective for an old disease. Annal of surgery, 239 (1); 2004. Rubino F, Marescaux J. Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes a new perspective for an old disease. Annal of surgery, 239 (1); 2004.
20.
Zurück zum Zitat Gautier JF, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with of type 2 diabetes. Diabetes Metab. 2005;31:233–42.PubMedCrossRef Gautier JF, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with of type 2 diabetes. Diabetes Metab. 2005;31:233–42.PubMedCrossRef
21.
Zurück zum Zitat Brethauer SA, Aminian A, Romero-Talamás H. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–37.PubMedCentralPubMed Brethauer SA, Aminian A, Romero-Talamás H. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–37.PubMedCentralPubMed
22.
Zurück zum Zitat Romero F, Nicolau J, Flores L. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012;26:2231–9.PubMedCrossRef Romero F, Nicolau J, Flores L. Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg Endosc. 2012;26:2231–9.PubMedCrossRef
23.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2∆DDCT method. Methods. 2001;25:402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2∆DDCT method. Methods. 2001;25:402–8.PubMedCrossRef
24.
Zurück zum Zitat Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.PubMedCentralPubMedCrossRef Guh DP, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Lee W, Chen C, Chong K. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011;7:683–90.PubMedCrossRef Lee W, Chen C, Chong K. Changes in postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and sleeve gastrectomy. Surg Obes Relat Dis. 2011;7:683–90.PubMedCrossRef
26.
Zurück zum Zitat Lee W, Hur KY, Lakadawala M. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg. 2012;16:45–52.PubMedCrossRef Lee W, Hur KY, Lakadawala M. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg. 2012;16:45–52.PubMedCrossRef
27.
Zurück zum Zitat Mottin CC, Padoin AV, Schroer CE, et al. Behavior of type 2 diabetes mellitus in morbid obese patients submitted to gastric bypass. Obes Surg. 2008;18:179–81.PubMedCrossRef Mottin CC, Padoin AV, Schroer CE, et al. Behavior of type 2 diabetes mellitus in morbid obese patients submitted to gastric bypass. Obes Surg. 2008;18:179–81.PubMedCrossRef
28.
Zurück zum Zitat Falkén Y, Hellstrom PM, Holst JJ. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227–35.PubMedCrossRef Falkén Y, Hellstrom PM, Holst JJ. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227–35.PubMedCrossRef
30.
Zurück zum Zitat Ranganath L, Norris F, Morgan L, et al. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci. 1999;96:335–42.PubMedCrossRef Ranganath L, Norris F, Morgan L, et al. Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36)amide secretion by circulating non-esterified fatty acids. Clin Sci. 1999;96:335–42.PubMedCrossRef
31.
Zurück zum Zitat Frank GR, Fox J, Candela N, et al. Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency. Mol Genet Metab. 2013;110(1–2):191–4.PubMedCentralPubMedCrossRef Frank GR, Fox J, Candela N, et al. Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency. Mol Genet Metab. 2013;110(1–2):191–4.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Choquet H, Stijnen P, Creemers JW. Genetic and functional characterization of PCSK1. Methods Mol Biol. 2011;768:247–53.PubMedCrossRef Choquet H, Stijnen P, Creemers JW. Genetic and functional characterization of PCSK1. Methods Mol Biol. 2011;768:247–53.PubMedCrossRef
33.
Zurück zum Zitat Creemers JWM, Choquet H, Stijnen P, et al. Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes. 2012;61(2):383–90.PubMedCentralPubMedCrossRef Creemers JWM, Choquet H, Stijnen P, et al. Heterozygous mutations causing partial prohormone convertase 1 deficiency contribute to human obesity. Diabetes. 2012;61(2):383–90.PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Jackson RS, Creemers JWM, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet. 1997;16:303–6.PubMedCrossRef Jackson RS, Creemers JWM, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet. 1997;16:303–6.PubMedCrossRef
35.
Zurück zum Zitat Jackson RS, Creemers JWM, Farooqi IS, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest. 2003;112:1550–60.PubMedCentralPubMedCrossRef Jackson RS, Creemers JWM, Farooqi IS, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest. 2003;112:1550–60.PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Jiménez A, Casamitjana R, Flores L, et al. GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg. 2013;257:894–9.PubMedCrossRef Jiménez A, Casamitjana R, Flores L, et al. GLP-1 and the long-term outcome of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery in morbidly obese subjects. Ann Surg. 2013;257:894–9.PubMedCrossRef
37.
Zurück zum Zitat Ezcurra M, Reimann F, Gribble FM, et al. Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol. 2013;13:1–6.CrossRef Ezcurra M, Reimann F, Gribble FM, et al. Molecular mechanisms of incretin hormone secretion. Curr Opin Pharmacol. 2013;13:1–6.CrossRef
38.
Zurück zum Zitat Benzinou M, Creemers JWM, Choquet H, et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat Genet. 2008;40(8):943–5.PubMedCrossRef Benzinou M, Creemers JWM, Choquet H, et al. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat Genet. 2008;40(8):943–5.PubMedCrossRef
Metadaten
Titel
Obesity Associated with Type 2 Diabetes Mellitus Is Linked to Decreased PC1/3 mRNA Expression in the Jejunum
verfasst von
Francieli Rohden
Cintia S. Costa
Thais O. Hammes
Rogério Margis
Alexandre V. Padoin
Cláudio C. Mottin
Regina Maria Guaragna
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 12/2014
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-014-1279-x

Weitere Artikel der Ausgabe 12/2014

Obesity Surgery 12/2014 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.